BACKGROUND: Health care cost continues to play a dominant role in our society. Technological advances are expensive, with the possible exception of stereotactic breast biopsy. We must learn other alternatives that give the same diagnostic accuracy at lower cost. The intention of this study was to find other acceptable alternatives to open excisional breast biopsies. METHODS: Patients were referred to Baylor University Medical Center between May 1990 and June 1992 for stereotactic breast biopsy of nonpalpable mammographic abnormalities. Before stereotactic biopsy, lesions were categorized into low or high suspicion for malignancy based on screening mammography. Slides were reviewed by a pathologist and the histological diagnosis was compared with mammographic characterization. Benign histology confirming the low-suspicion mammographic abnormality demonstrated mammographic and histologic correlation. Mammographic follow-up was recommended. RESULTS: Two hundred twenty-five women underwent 250 stereotactic breast biopsies. Malignancy was diagnosed in 47 patients; the remaining 203 lesions were benign on pathological examination and are being followed regularly. Seventy-eight percent of the lesions were characterized as low suspicion for malignancy, and 22% were characterized as high suspicion. The average cost savings per lesion using stereotactic biopsy was $1,629. CONCLUSION: Stereotactic breast biopsy is an acceptable, less expensive alternative to open excisional biopsy for diagnosing nonpalpable mammographic findings.
BACKGROUND: Health care cost continues to play a dominant role in our society. Technological advances are expensive, with the possible exception of stereotactic breast biopsy. We must learn other alternatives that give the same diagnostic accuracy at lower cost. The intention of this study was to find other acceptable alternatives to open excisional breast biopsies. METHODS:Patients were referred to Baylor University Medical Center between May 1990 and June 1992 for stereotactic breast biopsy of nonpalpable mammographic abnormalities. Before stereotactic biopsy, lesions were categorized into low or high suspicion for malignancy based on screening mammography. Slides were reviewed by a pathologist and the histological diagnosis was compared with mammographic characterization. Benign histology confirming the low-suspicion mammographic abnormality demonstrated mammographic and histologic correlation. Mammographic follow-up was recommended. RESULTS: Two hundred twenty-five women underwent 250 stereotactic breast biopsies. Malignancy was diagnosed in 47 patients; the remaining 203 lesions were benign on pathological examination and are being followed regularly. Seventy-eight percent of the lesions were characterized as low suspicion for malignancy, and 22% were characterized as high suspicion. The average cost savings per lesion using stereotactic biopsy was $1,629. CONCLUSION: Stereotactic breast biopsy is an acceptable, less expensive alternative to open excisional biopsy for diagnosing nonpalpable mammographic findings.
Authors: L Tabár; C J Fagerberg; A Gad; L Baldetorp; L H Holmberg; O Gröntoft; U Ljungquist; B Lundström; J C Månson; G Eklund Journal: Lancet Date: 1985-04-13 Impact factor: 79.321
Authors: Marvin J Stone; Billie E Aronoff; W Phil Evans; Joseph W Fay; Z H Lieberman; Carolyn M Matthews; George J Race; R Pickett Scruggs; C Allen Stringer Journal: Proc (Bayl Univ Med Cent) Date: 2003-01
Authors: R Schulz-Wendtland; P A Fasching; M R Bani; M P Lux; S Jud; C Rauh; C Bayer; D L Wachter; A Hartmann; M W Beckmann; M Uder; C R Loehberg Journal: Geburtshilfe Frauenheilkd Date: 2016-01 Impact factor: 2.915
Authors: J H Yim; P Barton; B Weber; D Radford; J Levy; B Monsees; F Flanagan; J A Norton; G M Doherty Journal: Ann Surg Date: 1996-06 Impact factor: 12.969